Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
GNVC's Cash to Debt is ranked higher than
97% of the 1248 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. GNVC: No Debt )
GNVC' s 10-Year Cash to Debt Range
Min: 0.83   Max: No Debt
Current: No Debt

Equity to Asset 0.83
GNVC's Equity to Asset is ranked higher than
85% of the 928 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. GNVC: 0.83 )
GNVC' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.89
Current: 0.83

0.35
0.89
Interest Coverage No Debt
GNVC's Interest Coverage is ranked higher than
90% of the 577 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GNVC: No Debt )
GNVC' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 4
Z-Score: -19.70
M-Score: -1.81
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -202.90
GNVC's Operating margin (%) is ranked higher than
66% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.88 vs. GNVC: -202.90 )
GNVC' s 10-Year Operating margin (%) Range
Min: -466.81   Max: -14.73
Current: -202.9

-466.81
-14.73
Net-margin (%) -192.62
GNVC's Net-margin (%) is ranked higher than
67% of the 1027 Companies
in the Global Biotechnology industry.

( Industry Median: -78.05 vs. GNVC: -192.62 )
GNVC' s 10-Year Net-margin (%) Range
Min: -432.31   Max: -11.32
Current: -192.62

-432.31
-11.32
ROE (%) -52.24
GNVC's ROE (%) is ranked higher than
68% of the 1143 Companies
in the Global Biotechnology industry.

( Industry Median: -35.75 vs. GNVC: -52.24 )
GNVC' s 10-Year ROE (%) Range
Min: -177.18   Max: -25.24
Current: -52.24

-177.18
-25.24
ROA (%) -40.35
GNVC's ROA (%) is ranked higher than
68% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: -28.24 vs. GNVC: -40.35 )
GNVC' s 10-Year ROA (%) Range
Min: -101.98   Max: -18.29
Current: -40.35

-101.98
-18.29
ROC (Joel Greenblatt) (%) -1106.98
GNVC's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 1223 Companies
in the Global Biotechnology industry.

( Industry Median: -438.40 vs. GNVC: -1106.98 )
GNVC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1883.37   Max: -192.56
Current: -1106.98

-1883.37
-192.56
Revenue Growth (%) -40.10
GNVC's Revenue Growth (%) is ranked higher than
62% of the 723 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. GNVC: -40.10 )
GNVC' s 10-Year Revenue Growth (%) Range
Min: -67   Max: 5.9
Current: -40.1

-67
5.9
EBITDA Growth (%) -7.30
GNVC's EBITDA Growth (%) is ranked higher than
75% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. GNVC: -7.30 )
GNVC' s 10-Year EBITDA Growth (%) Range
Min: -43.5   Max: 12.1
Current: -7.3

-43.5
12.1
EPS Growth (%) -7.40
GNVC's EPS Growth (%) is ranked higher than
76% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. GNVC: -7.40 )
GNVC' s 10-Year EPS Growth (%) Range
Min: -43.1   Max: 9.2
Current: -7.4

-43.1
9.2
» GNVC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2012

GNVC Guru Trades in Q4 2012

Jim Simons 10,900 sh (New)
» More
Q1 2013

GNVC Guru Trades in Q1 2013

Jim Simons 14,400 sh (+32.11%)
» More
Q2 2013

GNVC Guru Trades in Q2 2013

Jim Simons 22,500 sh (+56.25%)
» More
Q3 2013

GNVC Guru Trades in Q3 2013

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GNVC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.00
GNVC's P/B is ranked higher than
86% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 6.13 vs. GNVC: 3.00 )
GNVC' s 10-Year P/B Range
Min: 0.43   Max: 41.53
Current: 3

0.43
41.53
P/S 9.80
GNVC's P/S is ranked higher than
83% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 28.86 vs. GNVC: 9.80 )
GNVC' s 10-Year P/S Range
Min: 0.63   Max: 22.91
Current: 9.8

0.63
22.91
EV-to-EBIT -3.96
GNVC's EV-to-EBIT is ranked higher than
73% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GNVC: -3.96 )
GNVC' s 10-Year EV-to-EBIT Range
Min: -24.2   Max: 0.5
Current: -3.96

-24.2
0.5
Current Ratio 5.97
GNVC's Current Ratio is ranked higher than
78% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.74 vs. GNVC: 5.97 )
GNVC' s 10-Year Current Ratio Range
Min: 1.46   Max: 8.55
Current: 5.97

1.46
8.55
Quick Ratio 5.97
GNVC's Quick Ratio is ranked higher than
79% of the 1238 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GNVC: 5.97 )
GNVC' s 10-Year Quick Ratio Range
Min: 1.46   Max: 8.55
Current: 5.97

1.46
8.55

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.30
GNVC's Price/Net Cash is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 50.00 vs. GNVC: 3.30 )
GNVC' s 10-Year Price/Net Cash Range
Min: 0.9   Max: 34.6
Current: 3.3

0.9
34.6
Price/Net Current Asset Value 3.10
GNVC's Price/Net Current Asset Value is ranked higher than
94% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 29.38 vs. GNVC: 3.10 )
GNVC' s 10-Year Price/Net Current Asset Value Range
Min: 0.82   Max: 28.94
Current: 3.1

0.82
28.94
Price/Tangible Book 3.00
GNVC's Price/Tangible Book is ranked higher than
89% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 9.38 vs. GNVC: 3.00 )
GNVC' s 10-Year Price/Tangible Book Range
Min: 0.59   Max: 16.67
Current: 3

0.59
16.67
Price/Median PS Value 2.00
GNVC's Price/Median PS Value is ranked higher than
75% of the 1333 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. GNVC: 2.00 )
GNVC' s 10-Year Price/Median PS Value Range
Min: 0.17   Max: 4.02
Current: 2

0.17
4.02
Earnings Yield (Greenblatt) -25.80
GNVC's Earnings Yield (Greenblatt) is ranked higher than
55% of the 1218 Companies
in the Global Biotechnology industry.

( Industry Median: -6.30 vs. GNVC: -25.80 )
GNVC' s 10-Year Earnings Yield (Greenblatt) Range
Min: -25.8   Max: 16429.1
Current: -25.8

-25.8
16429.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GVC1.Germany,
Genvec Inc was incorporated under the laws of the state of Delaware on December 7, 1992.The Company is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. Its development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus or RSV, herpes simplex virus or HSV, and malaria. In the area of animal health the Company is developing vaccines against foot-and-mouth disease or FMD. In collaboration with Novartis, the Companys hearing and balance disorders program is focused on the restoration of hearing and balance function through the regeneration of critical cells of the inner ear. The Company is currently developing preventative vaccines, against RSV and malaria and therapeutic vaccine against HSV. The Company is developing vaccines against RSV, the single main viral cause of lower respiratory infections in infants and young children. It is developing vaccines for the prevention and treatment of HSV including HSV type 2 the virus responsible for cases of genital herpes. With its collaborators, the Company is generating vaccine candidates for the prevention of dengue fever. Dengue fever is a viral disease spread by mosquitoes that historically affected 50 million to 100 million people each year. With its collaborators the Company is generating vaccine candidates for the prevention of malaria. With its collaborators, the Company is developing vaccine and anti-viral candidates for the prevention and containment of FMD outbreaks. FMD is a contagious viral disease affecting cows and other animals with cloven hooves. The Company currently has two suppliers for its clinical manufacturing components, one for human health and one for animal health candidates. Currently it procures raw materials, including specialized components known as resins, for its product purification and testing methods from a limited number of suppliers. The Company faces intense competition from pharmaceutical and biotechnology companies, as well as academic and research institutions and government agencies both in the U.S. and abroad. The research, development, testing, manufacture, quality, safety, effectiveness, labeling, packaging, storage, approval, distribution, marketing, advertising, and promotion of any biologic products developed by the Company or its collaborators are subject to regulation by federal, state, local, and foreign governmental authorities.
» More Articles for GNVC

Headlines

Articles On GuruFocus.com
GenVec Inc. Reports Operating Results (10-K) Mar 11 2011 
GenVec Inc. Reports Operating Results (10-Q) May 07 2010 
GenVec Inc. Reports Operating Results (10-Q) Nov 06 2009 
GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants Aug 27 2009 
GenVec Inc. Reports Operating Results (10-Q) Aug 07 2009 
GenVec Inc. Reports Operating Results (10-Q) May 08 2009 

More From Other Websites
Nasdaq stocks posting largest volume increases Dec 18 2014
GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a... Dec 09 2014
GENVEC INC Financials Nov 21 2014
10-Q for GenVec, Inc. Nov 14 2014
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 12 2014
GenVec Reports Third Quarter 2014 Financial Results Nov 12 2014
GenVec Reports Third Quarter 2014 Financial Results Nov 12 2014
Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium Nov 11 2014
Preclinical Data For GenVec's RSV Vaccine Candidate Presented At The 9th RSV Symposium Nov 11 2014
GenVec Achieves Milestone In Hearing And Balance Collaboration Nov 05 2014
GenVec Achieves Milestone In Hearing And Balance Collaboration Nov 05 2014
GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers Nov 03 2014
Quinterol Mallette Appointed to GenVec Board Of Directors Oct 31 2014
Quinterol Mallette Appointed to GenVec Board Of Directors Oct 31 2014
GENVEC INC Files SEC form 8-K, Other Events Oct 29 2014
GENVEC INC Files SEC form 8-K, Change in Directors or Principal Officers Oct 20 2014
Zola P. Horovitz To Retire From GenVec Board Oct 20 2014
Zola P. Horovitz To Retire From GenVec Board Oct 20 2014
GENVEC INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Aug 12 2014
GenVec Reports Second Quarter 2014 Financial Results Aug 12 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK